Physician profile
Chad D Bartel
NPI 1720472970
$1,754.24
in general payments reported to CMS, 2019-2025
23 companies · $217 in 2025
The $217 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $68.76 · 2020: $101 · 2021: $161 · 2022: $360 · 2023: $349 · 2024: $498 · 2025: $217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,063.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,063.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $579.40 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $180.80 | 2020-2025 | Wegovy |
| Glaxosmithkline, LLC. | $114.62 | 2020-2025 | Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $106.11 | 2021-2024 | Mounjaro, Zepbound |
| Abbott Laboratories | $101.13 | 2022-2024 | Freestyle Libre 3 |
| Amgen INC. | $88.58 | 2024 | Repatha, Otezla |
| Pfizer INC. | $79.70 | 2022-2025 | |
| Astellas Pharma US INC | $72.78 | 2024-2025 | Veozah |
| Astrazeneca Pharmaceuticals Lp | $62.53 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.52 | 2022-2024 | Jardiance |
| Allergan, INC. | $47.93 | 2020 | |
| Sanofi Pasteur INC. | $42.63 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.99 | 2022-2024 | Xifaxan |
| Biohaven Pharmaceutical Holding Company Ltd. | $26.95 | 2022 | |
| Seqirus USA INC | $22.31 | 2025 | Fluad, Flucelvax |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $22.21 | 2022 | |
| Eisai INC. | $20.84 | 2021 | |
| Phathom Pharmaceuticals, INC. | $19.72 | 2024 | Voquezna |
| Gilead Sciences, INC. | $19.36 | 2025 | |
| Merck Sharp & Dohme LLC | $17.53 | 2023 | Dificid |
| Kowa Pharmaceuticals America, INC. | $14.47 | 2024 | Zoryve |
| Amarin Pharma, INC. | $13.23 | 2019 | |
| Shire North American Group INC | $12.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Bartel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.